Fastest Growing Companies 2015

Growth eclipse

After a dream run, Sun Pharma is grappling with growth and regulatory issues. Can the country’s biggest drug maker rediscover its mojo?

Soumik Kar

Form 483 has been a source of chronic pain for Indian pharma companies that have a major presence in the US. Issued by the US food and drug administration (USFDA), the form notifies a company of objectionable conditions found at its drug units. At the conclusion of an inspection, companies have to respond to the US regulator about their corrective action plan and then implement these plans expeditiously.